Objective
The current study examines whether antidepressants, contrary to current thinking, are safe and effective treatments for generalized anxiety disorder (GAD) not complicated by depression or panic disorder.
Design
Randomized, double-blind, placebocontrolled, flexible-dose, 8-week treatment study comparing imipramine hydrochloride (mean maximum daily dose, 143 mg), trazodone hydrochloride (255 mg), and diazepam (26 mg).
Patients
Two hundred thirty patients with a DSM-III diagnosis of GAD in whom major depression and panic disorder has been excluded, and who had a Hamilton Anxiety Scale total score of at least 18.
Setting
Seventy-five percent of patients were treated in family practice settings in the community, with the remainder treated in psychiatric practices, either academic or private.
Results
Patients treated with diazepam showed the most improvement in anxiety ratings during the first 2 weeks of treatment, with somatic symptoms being most responsive. From week 3 through week 8 trazodone achieved comparable, and imipramine somewhat better, anxiolytic efficacy when compared with diazepam, with psychic symptoms of tension, apprehension, and worry being more responsive to the antidepressants. Among completers, moderate to marked improvement was reported by 73% of patients treated with imipramine, 69% of patients treated with trazodone, 66% of patients treated with diazepam, but only 47% of patients treated with placebo. Overall, patients treated with antidepressants reported a higher rate of adverse effects than diazepam-treated patients, but attention rates were the same across all treatments.
Conclusions
The results of the study need replication, but suggest a potentially important role for antidepressants, particularly imipramine, in patients suffering from GAD.
Special issue on CNS experimental medicine
Dawson et al.
J Psychopharmacol 2011;25:1145-1147.
FULL TEXT
Time to Relapse After 6 and 12 Months' Treatment of Generalized Anxiety Disorder With Venlafaxine Extended Release
Rickels et al.
Arch Gen Psychiatry 2010;67:1274-1281.
ABSTRACT
| FULL TEXT
Review: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)
Davidson et al.
J Psychopharmacol 2010;24:3-26.
ABSTRACT
Pregabalin and venlafaxine improve symptoms of generalised anxiety disorder
Stein
Evid. Based Ment. Health 2007;10:23-23.
FULL TEXT
Mirtazapine treatment of Generalized Anxiety Disorder: a fixed dose, open label study
Gambi et al.
J Psychopharmacol 2005;19:483-487.
ABSTRACT
Antidepressant drugs in the treatment of anxiety disorders
Scott et al.
Adv. Psychiatr. Treat. 2001;7:275-282.
FULL TEXT
Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study
ALLGULANDER et al.
Br. J. Psychiatry 2001;179:15-22.
ABSTRACT
| FULL TEXT
The Quality of Care for Depressive and Anxiety Disorders in the United States
Young et al.
Arch Gen Psychiatry 2001;58:55-61.
ABSTRACT
| FULL TEXT
Extracts from "Clinical Evidence": Anxiety disorder
Gale and Oakley-Browne
BMJ 2000;321:1204-1207.
FULL TEXT
Efficacy of Venlafaxine Extended-Release Capsules in Nondepressed Outpatients With Generalized Anxiety Disorder: A 6-Month Randomized Controlled Trial
Gelenberg et al.
JAMA 2000;283:3082-3088.
ABSTRACT
| FULL TEXT
A Decision Analysis for an end of Phase II Go/Stop Decision
Pallay and Berry
Drug Information Journal 1999;33:821-833.
ABSTRACT
Fortnightly Review: Treatment of anxiety
Lader
BMJ 1994;309:321-324.
FULL TEXT
